Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
Daniel L. Hertz, D. Max Smith, Stuart A. Scott, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 768-779
Open Access | Times Cited: 23

Showing 23 citing articles:

Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing
Amy Turner, Cyrine E. Haidar, Wenjian Yang, et al.
Clinical and Translational Science (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 24
Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology
Sharon P. Shriver, Devon V. Adams, Brittany A. McKelvey, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 10, pp. 1181-1192
Open Access | Times Cited: 13
Binding Pattern and Structural Interactome of the Anticancer Drug 5-Fluorouracil: A Critical Review
En‐Shyh Lin, Cheng-Yang Huang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3404-3404
Open Access | Times Cited: 5
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center
D. Grace Nguyen, Sarah Morris, Alicia Hamilton, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 4
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
R COOPERDEHOFF, D. Max Smith, Christina L. Aquilante, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial
Sarah Glewis, Michael Michael, Howard Gurney, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Patient perspectives of a multidisciplinary Pharmacogenomics clinic
Lindy Maska, Roseann S. Donnelly, Benjamin J. Kerman, et al.
Pharmacogenomics (2025), pp. 1-13
Closed Access
Application of dihydropyrimidine dehydrogenase deficiency testing for the prevention of fluoropyrimidine toxicity: a real-world experience in a Southern Italy cancer center
Gabriella Bianchino, A. Perrone, Donatella Lucchetti, et al.
Journal of Chemotherapy (2025), pp. 1-7
Closed Access
Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US
Tabea Tracksdorf, D. Max Smith, Skyler Pearse, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 8
Closed Access | Times Cited: 3
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation
Larisa H. Cavallari, J. Kevin Hicks, Jai N. Patel, et al.
Pharmacogenetics and Genomics (2024) Vol. 35, Iss. 1, pp. 1-11
Closed Access | Times Cited: 2
Understanding the Biology and Testing Techniques for Pharmacogenomics in Oncology: A Practical Guide for the Clinician
Nury Steuerwald, Sarah Morris, D. Grace Nguyen, et al.
JCO Oncology Practice (2024) Vol. 20, Iss. 11, pp. 1441-1451
Closed Access | Times Cited: 2
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
Angela Wu, H Anderson, Curtis Hughesman, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
A Narrative Review on Pharmacogenomics in Psychiatry
Sara Palumbo, Veronica Mariotti, Silvia Pellegrini
Journal of Clinical Psychopharmacology (2023) Vol. 44, Iss. 1, pp. 49-56
Open Access | Times Cited: 4
Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system
Ruiqi Zhao, Mengyao Han, Sen Lin, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1295-1307
Closed Access | Times Cited: 1
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer
Rossana Roncato, Alessia Bignucolo, Elena Peruzzi, et al.
JAMA Network Open (2024) Vol. 7, Iss. 12, pp. e2449441-e2449441
Closed Access | Times Cited: 1
Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives
Meghna Bhatt, Beth N. Peshkin, Sadaf Kazi, et al.
Pharmacogenomics (2023) Vol. 24, Iss. 16, pp. 859-870
Closed Access | Times Cited: 2
Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States
Tabea Tracksdorf, D. Max Smith, Skyler Pearse, et al.
Research Square (Research Square) (2024)
Open Access
Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy
Çıgır Biray Avci, Bakiye Göker Bağca, Behrouz Shademan, et al.
Functional & Integrative Genomics (2024) Vol. 24, Iss. 5
Closed Access
CLINICAL IMPACT OF DPYD GENOTYPING AND DOSE ADJUSTMENT IN CANDIDATES FOR FLUOROPYRIMIDINE TREATMENT
Ana Hernández-Guío, Miguel Ángel Calleja‐Hernández, Andrés Corno-Caparrós, et al.
Heliyon (2024) Vol. 10, Iss. 23, pp. e40808-e40808
Closed Access
Pharmacogenomics: DPYD and Prevention of Toxicity
J H Keen, John McDermott, Elisa Aguilar-Martínez, et al.
Clinical Oncology (2024) Vol. 38, pp. 103706-103706
Closed Access
The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy
Jacob T. Brown, Micheline Andel Goldwire, Amanda Massmann, et al.
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2024)
Open Access
Why is There Still Debate About Recommending DPYD‐Testing Before Fluoropyrimidine Treatment?
Ingolf Cascorbi
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 733-737
Open Access | Times Cited: 1
Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles
J. Quesada Granados, Amy L. Pasternak, N. Lynn Henry, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 3, pp. 452-456
Open Access | Times Cited: 1
Page 1

Scroll to top